Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| platelet | 9 studies | 33% ± 12% | |
| megakaryocyte | 3 studies | 36% ± 15% |
Insufficient scRNA-seq data for expression of PF4V1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 66% | 10.30 | 59 / 89 | 72% | 8.26 | 650 / 901 |
| spleen | 99% | 49.17 | 238 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 78% | 74.34 | 724 / 929 | 0% | 0 | 0 / 0 |
| liver | 49% | 6.53 | 111 / 226 | 26% | 3.08 | 107 / 406 |
| lung | 52% | 7.13 | 300 / 578 | 22% | 1.28 | 250 / 1155 |
| prostate | 57% | 6.65 | 140 / 245 | 11% | 0.18 | 54 / 502 |
| intestine | 16% | 1.76 | 156 / 966 | 19% | 0.49 | 98 / 527 |
| skin | 27% | 20.33 | 494 / 1809 | 6% | 0.21 | 27 / 472 |
| bladder | 14% | 0.86 | 3 / 21 | 16% | 0.88 | 79 / 504 |
| esophagus | 10% | 0.89 | 144 / 1445 | 20% | 0.76 | 36 / 183 |
| breast | 22% | 2.62 | 101 / 459 | 3% | 0.05 | 31 / 1118 |
| uterus | 5% | 0.39 | 8 / 170 | 19% | 1.83 | 89 / 459 |
| pancreas | 5% | 0.34 | 16 / 328 | 19% | 0.37 | 33 / 178 |
| stomach | 3% | 0.19 | 11 / 359 | 20% | 0.57 | 56 / 286 |
| ovary | 1% | 0.07 | 2 / 180 | 11% | 0.35 | 49 / 430 |
| brain | 5% | 0.41 | 140 / 2642 | 4% | 0.09 | 27 / 705 |
| adipose | 7% | 0.55 | 85 / 1204 | 0% | 0 | 0 / 0 |
| adrenal gland | 3% | 0.28 | 9 / 258 | 3% | 0.12 | 6 / 230 |
| tonsil | 0% | 0 | 0 / 0 | 4% | 0.17 | 2 / 45 |
| heart | 4% | 0.33 | 38 / 861 | 0% | 0 | 0 / 0 |
| thymus | 4% | 0.23 | 23 / 653 | 1% | 0.02 | 5 / 605 |
| blood vessel | 4% | 0.32 | 57 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.01 | 2 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0070098 | Biological process | chemokine-mediated signaling pathway |
| GO_0006954 | Biological process | inflammatory response |
| GO_0005615 | Cellular component | extracellular space |
| GO_0045236 | Molecular function | CXCR chemokine receptor binding |
| GO_0008201 | Molecular function | heparin binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0008009 | Molecular function | chemokine activity |
| Gene name | PF4V1 |
| Protein name | Platelet factor 4 variant (C-X-C motif chemokine 4 variant) (CXCL4L1) (PF4alt) (PF4var1) [Cleaved into: Platelet factor 4 variant(4-74); Platelet factor 4 variant(5-74); Platelet factor 4 variant(6-74)] |
| Synonyms | SCYB4V1 CXCL4V1 |
| Description | FUNCTION: Inhibitor of angiogenesis. Inhibitor of endothelial cell chemotaxis (in vitro). . |
| Accessions | P10720 ENST00000226524.4 |